肿瘤坏死因子相关诱导凋亡配体的临床应用  

Clinical Application of TRAIL Research

作　　者：夏阳 李谦[1] 

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京210009

出　　处：《药物生物技术》2015年第5期452-456,共5页Pharmaceutical Biotechnology

基　　金：江苏省六大人才高峰资助;江苏高校优势学科建设工程资助

摘　　要：肿瘤坏死因子相关凋亡诱导配体(TRAIL)作为一种新型抗肿瘤药物,对肿瘤细胞的凋亡具有选择性毒性,且对正常细胞无毒性,因而具有作为肿瘤的广谱治疗药物的潜力,是近年来蛋白类抗肿瘤药物的研究热点。文章从TRAIL及其受体的结构功能、近期对于TRAIL的实验及临床研究入手,综述TRAIL诱导细胞特别是肿瘤细胞凋亡的凋亡通路、作用机制及其用于肿瘤治疗的临床应用前景。The tumor necrosis factor related apoptosis inducing ligand（TRAIL） is a new type of anti-tumor agent. It has selective toxicity for the apoptosis of tumor cells and non-toxic for normal ceils. Therefore tumor necrosis factor related apoptosis inducing ligand has the potential as a broad-spectrum therapy for anti-tumors, given that it becomes the hot spot for bio-technology research in recent years for protein anti-neoplastic agents. In this review, based on the structure and function of the TRAIL and its receptors, from the clinical trial and application for anti-tumor in recent years of TRAIL for experimental and clinical studies, this article was reviewed on the tumor necrosis factor related apoptosis inducing ligand inducing the apoptosis pathway of cells, especially the tumor cells, and the mechanism of ligand-receptor action and clinical application prospect for anti-tumor treatment of TRAIL.

关 键 词：肿瘤坏死因子相关诱导凋亡配体 细胞凋亡 临床治疗 

分 类 号：Q511[生物学—生物化学]